Erythrocyte or whole-blood folate concentrations represent whole-body folate stores and are used to assess folate status. We and others have shown that the 5,10-methylenetetrahydrofolate reductase (NADPH) (MTHFR) 677CϾT mutation results in accumulation of reduced folates other than 5-methyltetrahydrofolic acid (5CH 3 THF), which is the predominant folate form usually found in mature erythrocytes (1) (2) (3) (4) (5) . Under conditions of impaired folate status, the T/T genotype has been associated with increased risk of neural tube defects, colorectal neoplasias, and possibly cardiovascular disease (6 ) . An earlier report raised concerns that the variation of erythrocyte folate in MTHFR polymorphism is related to the assay used (7 ) . The Bio-Rad QuantaPhase II radioassay (BR), used since 1991 to monitor the folate status of the US population through the National Health and Nutrition Examination Survey (NHANES), was discontinued in 2007; 2 new methods are now employed, liquid chromatographytandem mass spectrometry (LC-MS/MS) 1 (3, 8, 9 ) and the microbiologic assay (10, 11 ) . We used 3 different assays to investigate the influence of the MTHFR polymorphism on whole-blood folate pattern and response, and we assessed whether regression equations could be derived for future time trend analyses of NHANES.
To cover a wide range of folate concentrations, we purchased EDTA anticoagulated whole blood samples from 2 blood banks. These specimens included 96 and 75 samples from US and European blood donors, respectively, collected in spring 2006. We also purchased nonanticoagulated whole blood samples from the US blood bank to prepare matching serum samples. Whole blood samples were stored at Ϫ70°C before hemolysis with 1% (wt/vol) L-ascorbic acid, pH 2.7 (1:11 dilution). The same hemolysate, incubated at 37°C for 4 h to ensure complete folate deconjugation (8 ) and then frozen at Ϫ70°C, was used for LC-MS/MS folate pattern analysis and for total folate (TFOL) analysis by microbiologic assay. A hemolysate without incubation was used for the BR; the manufacturer states that no incubation is needed if the he- molysate is frozen and assayed later. MTHFR C677T (rs1801133) polymorphism was genotyped using the MGB Eclipse™ probe system (Nanogen) (12 ) . We analyzed the data with SAS (version 9; SAS Institute) and Analyze-it for Microsoft Excel software. The effect of genotype (C/C, C/T, and T/T) and data set (US and Europe) on TFOL concentrations was studied by 2-factor ANOVA for each method separately. For descriptive statistics, each data set was analyzed separately. In addition to individual folate species, we also calculated the ratio of 5CH 3 THF to TFOL and of reduced folates other than 5CH 3 THF [non-5CH 3 THF; sum of 5-formyltetrahydrofolic acid (5CHOTHF), 5,10-methenyltetrahydrofolic acid (5,10CHϭTHF), and tetrahydrofolic acid (THF)] to TFOL, as described previously (1) (2) (3) (4) (5) . To compare the methods, we used the sum of folate species determined by LC-MS/MS and TFOL determined by microbiologic assay or BR. Method regression equations are presented only for the combined set because we found no differences between the 2 data sets other than the concentration ranges. Methods were compared by least-squares regression, after log-transformation of the data, to account for nongaussian distribution. As in our method comparison paper for serum folate (13 ), we developed multiple linear regression models that used a dummy binary variable (0, 1), IND, to account for intercept differences, and an interaction variable (INDϫlog 10 microbiologic assay) to account for differences in slope over 2 discrete concentration intervals (cutoff of 370 nmol/L for microbiologic assay representing the median concentration). The fit of the models was evaluated by comparing the sum of squared residuals (SSR) to the predicted residual sum of squares (PRESS). We tested the recoveries of the microbiologic assay and BR methods by adding each of the 5 folate calibrators (Merck Eprova) at 10 nmol/L [in 1% (wt/vol) L-ascorbic acid, pH 2.7, for microbiologic assay and in protein diluent for BR] to a whole-blood hemolysate pool.
The concentrations of folate species in whole blood were higher in the US than in the European sample set, as was the median (range) TFOL concentration by LC-MS/MS [378 (228 -820) nmol/L, US set (n ϭ 96); 250 (122-582) nmol/L, European set (n ϭ 75)] ( Table 1 ). The relative whole-blood folate pattern [median (range)] was similar for individuals with C/C (n ϭ 73) and C/T (n ϭ 66) genotype, regardless of the sample set: 88% (71%-91%) and 86% (50%-91%), respectively, for 5CH 3 THF vs 12% (9%-29%) and 14% (9%-51%) for non-5CH 3 THF (see also Fig. 1 in Data Supplement). Individuals with T/T (n ϭ 32) genotype displayed 58% (22%-87%) 5CH 3 THF vs 42% (13%-78%) non-5CH 3 THF forms, with 5,10CHϭTHF being the largest contributor to the non-5CH 3 THF portion. We did not find differences in serum folate pattern or TFOL by genotype (see Table 1 in the Data Supplement).
We found a significant effect of data set (P Ͻ0.001) on TFOL concentrations determined by LC-MS/MS or microbiologic assay, but no effect of genotype and no genotype ϫ data set interaction [see Fig. 2 (Fig. 1A) . The SSR (0.5406) agreed with the PRESS (0.5679).
The BR assay produced lower results than the other 2 assays. Because of a significant genotype ϫ data set interaction (P ϭ 0.0041), the 2-factor ANOVA for this assay was followed by 1-factor ANOVA, looking at the effect of genotype in each data set separately. In both data sets, genotype had a significant effect on TFOL concentrations determined by BR (US, P ϭ 0.0424, C/T different from T/T; Europe, P ϭ 0.0081, C/C different from T/T) [see Fig. 2 in the Data Supplement for scatter plots by genotype (panel B) and by data set (panel D)]. We therefore analyzed the data separately for C/CϩC/T and T/T genotype. We also present data based on all genotypes. The BR and microbiologic assays showed a correlation of r ϭ 0.87 for all genotypes, r ϭ 0.94 for C/CϩC/T, and r ϭ 0.88 for T/T, but BR produced lower values, resulting in a significant negative concentration dependent difference: Ϫ45% for all genotypes (95% CI, Ϫ46% to Ϫ43%; 2 SD limits of agreement, Ϫ62% to Ϫ20% based on log 10 -transformed Bland Altman analysis); Ϫ48% for C/CϩC/T (95% CI, Ϫ46% to Ϫ43%; 2 SD limits of agreement, Ϫ62% to Ϫ20%); Ϫ31% for T/T (95% CI, Ϫ35% to Ϫ26%; 2 SD limits of agreement, Ϫ52% to 0%). The multiple linear regression equations were as follows: (Fig. 1B) . our previous report of recoveries in serum samples (13 ) . The BR showed satisfactory recovery (n ϭ 2 days) for 5,10CH The current study investigated the influence of MTHFR C677T polymorphism on whole blood folate pattern and response by 3 different assays. As reported previously (1) (2) (3) (4) (5) , our results confirm that individuals with the T/T genotype showed an accumulation of non-5CH 3 THF forms (approximately 30%-40%) in their whole blood. The novelty of this study is that it analyzed whole blood from a larger number of individuals with T/T genotype (n ϭ 32) and that it considered data from the US, where folate fortification has been in place for almost a decade, and from Europe, where the folate status of the population is lower due to the absence of widespread fortification. Interestingly, the TFOL concentration by either LC-MS/MS or microbiologic assay was not affected by the genotype in either sample set. Previous reports showed lower erythrocyte folate concentrations in individuals with T/T vs C/C genotype, only when folate status was low (below the median of the studied population or excluding patients taking vitamins) (2, 13 ) . Thus, our finding indicates that the folate status of the individuals in the European sample set might be adequate. We confirmed previous findings of high interindividual variability in non-5CH 3 THF accumulation in individuals with the T/T genotype (from Ͻ20% to 80% of TFOL) (4 -5 ) . We observed less interindividual variability in individuals with the C/C or C/T genotype for the European set than for the US set. Owing to the lack of a genotype effect for the LC-MS/MS and microbiologic assay, we were able to provide one regression equation that was applicable to a wide concentration range and that covers populations with and without folate fortification. However, we had to use separate equations for the BR assay depending on genotype. The equation for all genotypes will provide only a rough estimate in situations in which genotype information is not available.
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